Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2025 Jun 17;333(23):2073-2082.
doi: 10.1001/jama.2025.5129.

Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial

Chan Joo Lee  1 , Sang-Hyun Ihm  2 , Dong-Ho Shin  3 , Jin-Ok Jeong  4 , Ju Han Kim  5 , Kyeong-Hyeon Chun  6   7 , JiWung Ryu  8   9 , Hae-Young Lee  10 , Seonghoon Choi  9 , Eun Mi Lee  11 , Jung Hyun Choi  12 , Kwang-Il Kim  13 , Jinho Shin  14 , Wook Bum Pyun  15 , Dae-Hee Kim  16 , Sungha Park  1 , Bryan Williams  17
Affiliations
Clinical Trial

Spironolactone vs Amiloride for Resistant Hypertension: A Randomized Clinical Trial

Chan Joo Lee et al. JAMA. .

Abstract

Importance: Amiloride has been proposed as an alternative to spironolactone for treating resistant hypertension. However, no randomized clinical trials have compared the efficacy of spironolactone and amiloride in patients with resistant hypertension.

Objective: To determine whether amiloride is noninferior to spironolactone in reducing home-measured systolic blood pressure (SBP) in patients with resistant hypertension.

Design, setting, and participants: Prospective, open-label, blinded end-point randomized clinical trial conducted at 14 sites in South Korea. From November 16, 2020, to February 29, 2024, 118 patients with home SBP of 130 mm Hg or greater after a 4-week run-in period with a fixed-dose triple medication combination (angiotensin receptor blocker, calcium channel blocker, and thiazide) were enrolled.

Intervention: Patients were randomized in a 1:1 ratio to receive 12.5 mg/d of spironolactone (n = 60) or 5 mg/d of amiloride (n = 58). If home SBP remained 130 mm Hg or greater and serum potassium was less than 5.0 mmol/L after 4 weeks, dosages were increased to 25 mg/d and 10 mg/d, respectively.

Main outcomes and measures: The primary end point was the between-group difference in home SBP change at week 12, with a noninferiority margin of -4.4 mm Hg for the lower bound of the confidence interval. Secondary end points included achievement rates of home- and office-measured SBP of less than 130 mm Hg.

Results: The median age of the study population was 55 years, with 70% male. There were no differences between groups in demographic characteristics other than use of α-blockers (8.6% in the amiloride group and 0% in the spironolactone group). The mean baseline home SBPs were 141.5 (SD, 7.9) mm Hg and 142.3 (SD, 8.5) mm Hg in the amiloride and spironolactone groups, respectively. At week 12, mean home SBP measurements were changed from baseline by -13.6 (SD, 8.6) mm Hg and -14.7 (SD, 11.0) mm Hg in the amiloride and spironolactone groups, respectively (between-group difference in change, -0.68 mm Hg; 90% CI, -3.50 to 2.14 mm Hg), with amiloride demonstrating noninferiority to spironolactone. Home-measured achievement rates of SBP less than 130 mm Hg in the amiloride and spironolactone groups were 66.1% and 55.2%, respectively, and office-measured achievement rates of SBP less than 130 mm Hg were 57.1% and 60.3%, respectively, with no difference between the 2 groups. One case of hyperkalemia-related discontinuation occurred in the amiloride group, with no cases of gynecomastia in either group.

Conclusions and relevance: Amiloride was noninferior to spironolactone in lowering home SBP, suggesting that it could be an effective alternative for treatment of resistant hypertension.

Trial registration: ClinicalTrials.gov Identifier: NCT04331691.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr C. J. Lee reported receipt of personal fees from Novartis, Hanmi Pharmaceutical, Yuhan, Boryung Pharmaceutical, and Daiichi Sankyo and stock options from Mediwhale. Dr Chun reported receipt of personal fees from Amgen, Astra Zeneca, Boehringer Ingelheim, Boryung, Chong Kun Dang, Daewon, Daewoong, GC Biopharma, Handok, Hanlim, Jeilpharm, JW Pharmaceutical, Novartis, Organon, Servier, Viatris, and Yuhan. Dr Ryu reported receipt of grants from Daiichi Sankyo Korea Co Ltd outside the submitted work. Dr E. M. Lee reported receipt of grants from Daiichi Sankyo and the Korean National Health and Nutritional Examination Survey. Dr J. H. Choi reported receipt of grants from Daiichi Sankyo Korea Co Ltd and the Korea National Institute of Health outside the submitted work. Dr K.-I. Kim reported receipt of grants from Daewoong, Yuhan, Shingpoong, and AddPharma. Dr J. Shin reported receipt of personal fees from Inno.N, Daewoong, Boryung, Hanmi, BMS, Novartis, and Menarini and grants from AstraZeneca. Dr D.-H. Kim reported receipt of honoraria from Viatris, Organon, Boryung, Hanmi, Daewoong, Celltrion, Daiichi Sankyo, and Chong Kun Dang and a research grant from Daewoong. Dr Park reported receipt of personal fees from Viatris, Organon, Boryung, Handok, Hanmi, Daewoong, Donga, Celltrion, Servier, Daiichi Sankyo, and Skylabs and stock options from Mediwhale. Dr Williams reported steering committee membership for AstraZeneca, Novartis, and Alnylam. No other disclosures were reported.

Comment in

References

    1. Carey RM, Sakhuja S, Calhoun DA, Whelton PK, Muntner P. Prevalence of apparent treatment-resistant hypertension in the United States. Hypertension. 2019;73(2):424-431. doi: 10.1161/HYPERTENSIONAHA.118.12191 - DOI - PMC - PubMed
    1. Park S, Shin J, Ihm SH, et al. Resistant hypertension: consensus document from the Korean Society of Hypertension. Clin Hypertens. 2023;29(1):30. doi: 10.1186/s40885-023-00255-4 - DOI - PMC - PubMed
    1. Carey RM, Calhoun DA, Bakris GL, et al. ; American Heart Association Professional/Public Education and Publications Committee of the Council on Hypertension, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Genomic and Precision Medicine, Council on Peripheral Vascular Disease, Council on Quality of Care and Outcomes Research, and Stroke Council . Resistant hypertension: detection, evaluation, and management: a scientific statement from the American Heart Association. Hypertension. 2018;72(5):e53-e90. doi: 10.1161/HYP.0000000000000084 - DOI - PMC - PubMed
    1. Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105(2):98-105. doi: 10.1136/heartjnl-2018-313599 - DOI - PubMed
    1. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125(13):1635-1642. doi: 10.1161/CIRCULATIONAHA.111.068064 - DOI - PMC - PubMed

MeSH terms

Supplementary concepts

Associated data